证券代码：600488 证券简称：津药药业 公告编号：2025-022 津药药业股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 召开的日期时间：2025 年 4 月 16 日 14 点 00 分 召开地点：天津经济技术开发区黄海路 221 号津药药业办公楼六楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 股东大会召开日期：2025 年 4 月 16 日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供的 股东大会提醒服务，委托上证信息通过智能短信等形式，根据股权登记 日的股东名册主动提醒股东参会投票，向每一位投资者主动推送股东会 参会邀请、议案情况等信息。 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年年度股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场 ...

证券代码：600488 证券简称：津药药业 编号：2025-016 津药药业股份有限公司（以下简称"公司"）第九届监事会第十一次 会议于 2025 年 3 月 25 日以现场与通讯表决相结合的方式召开。会议由 监事会主席赵炜先生主持，应参加表决监事 3 人，实际表决监事 3 人。 会议符合《中华人民共和国公司法》和《公司章程》的有关规定。会议 经过审议，决议如下： 1.审议通过《2024 年度监事会工作报告》 表决结果：同意【3】票，反对【0】票，弃权【0】票。此项议案需 提交公司 2024 年年度股东大会审议。 2.审议关于监事 2024 年度薪酬总额的议案 公司监事 2024 年度薪酬总额是依据公司所处的行业、规模的薪酬水 平，结合公司的实际经营情况制定和执行的，程序合法、有效，不存在 损害公司及股东利益的情形，符合国家有关法律、法规及《公司章程》 的规定。此项议案全体监事回避表决。直接提交公司 2024 年年度股东大 会审议。 3.审议通过《2024 年度财务决算草案》 表决结果：同意【3】票，反对【0】票，弃权【0】票。此项议案需 提交公司 2024 年年度股东大会审议。 4.审议通过《2024 年度 ...

证券代码：600488 证券简称：津药药业 编号：2025-015 津药药业股份有限公司 第九届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）第九届董事会第十五次 会议于 2025 年 3 月 25 日以现场和通讯表决相结合的方式召开。本次会 议的通知已于 2025 年 3 月 14 日以电子邮件的方式送达公司各位董事、 监事和高管人员。会议应参加表决董事 9 人，实际表决董事 9 人，公司 监事及高管人员列席了会议。会议符合《中华人民共和国公司法》和《公 司章程》的有关规定，决议如下： 1.审议通过《2024 年度总经理工作报告》 表决结果：同意【9】票，反对【0】票，弃权【0】票。 2.审议通过《2024 年度董事会工作报告》 表决结果：同意【9】票，反对【0】票，弃权【0】票。本议案需提 交公司 2024 年年度股东大会审议。 3.审议通过《2024 年度财务决算草案》 表决结果：同意【9】票，反对【0】票，弃权【0】票。本议案需提 交公司 20 ...

Financial Performance - In 2023, net profit increased by 230.60% year-on-year, with further performance improvement expected in 2024[6]. - The company's operating revenue for 2024 was CNY 3,215,285,232.59, a decrease of 15.00% compared to CNY 3,782,826,621.15 in 2023[31]. - Net profit attributable to shareholders for 2024 was CNY 133,450,642.68, an increase of 14.01% from CNY 117,052,520.50 in 2023[31]. - The net cash flow from operating activities decreased by 27.28% to CNY 569,371,797.90 in 2024 from CNY 783,008,315.33 in 2023[31]. - The total assets as of the end of 2024 were CNY 5,698,286,373.15, a decrease of 7.23% from CNY 6,142,482,199.13 at the end of 2023[31]. - Basic earnings per share for 2024 increased to CNY 0.122, up 14.02% from CNY 0.107 in 2023[32]. - The weighted average return on net assets for 2024 was 4.45%, an increase of 0.50 percentage points from 3.95% in 2023[32]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 136,288,020.42, a 27.11% increase from CNY 107,223,594.29 in 2023[31]. - The net assets attributable to shareholders at the end of 2024 were CNY 3,057,347,087.18, an increase of 3.51% from CNY 2,953,554,191.30 at the end of 2023[31]. Market Presence and Expansion - The company has 60% of its steroid hormone raw materials exported to over 70 countries and regions across Asia, Europe, and America, with domestic sales covering nearly 100 cities[8]. - The company plans to continue expanding its overseas market presence and has received GMP certification for several products in Brazil and the USA[8]. - The company is committed to becoming a leader in emergency and cold standby drugs, ensuring drug safety and accessibility[9]. - The company is actively responding to new safety production regulations, improving its safety management system, and investing in automation upgrades and dual prevention systems[56]. - The company is focusing on developing new products in the emergency medication sector, including a range of injectable solutions[156]. Research and Development - Five products have received drug registration certificates from the National Medical Products Administration in 2024, and ten products have passed the consistency evaluation of generic drug quality and efficacy[9]. - R&D investment for 2024 reached 248 million RMB, accounting for 7.7% of total operating revenue[44]. - The company applied for 18 patents and received 18 patent authorizations during the reporting period, indicating a strong focus on innovation and product development[65]. - The company is conducting ongoing research and development on various new products, including amino acid drugs and broad-spectrum antibiotics, with several in different stages of approval[112]. - The company has a pipeline of new drug applications, including XP0021, which is under review for severe allergic conditions and acute rejection reactions[116]. Operational Efficiency and Management - The company aims to enhance operational efficiency by compressing management levels and optimizing resource allocation[6]. - The company has implemented various cost reduction strategies, resulting in a 13.45% decrease in operating costs[74]. - Sales expenses decreased by 45.76% due to improved management and optimized sales models[74]. - The company has strengthened internal management through lean production and process optimization, aiming to reduce costs and improve efficiency[62]. - The company has implemented a new CRM system to enhance operational sales management capabilities[43]. Compliance and Governance - The company will focus on compliance and internal control to support sustainable development in the face of evolving market challenges[10]. - The company has established a compliance management system to enhance its ability to identify and manage compliance risks[48]. - The company achieved a 100% compliance rate in information disclosure, with zero errors in 2024[174]. - The company maintained a sound corporate governance structure with independent organizational entities, ensuring compliance with laws and regulations[177]. Awards and Recognition - The company has been recognized in the top 100 of the 2024 China Drug R&D Comprehensive Strength Ranking and the 2024 China Chemical Drug R&D Strength Ranking[9]. - The company received 8 awards for quality management at national and municipal levels in 2024[45]. - The company was recognized in the "2024 China Pharmaceutical R&D Comprehensive Strength Ranking" and the "2024 China Chemical Pharmaceutical R&D Strength Ranking" as part of the top 100[49]. Strategic Initiatives - The company plans to focus on new product development and market expansion strategies in the upcoming year[22]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies in the biopharmaceutical sector[101]. - The company is enhancing its digital marketing efforts, with an investment of 50 million yuan to increase brand visibility[101]. - The company is actively pursuing mergers and acquisitions to enhance its portfolio and market share in the pharmaceutical industry[130]. Financial Management - The company achieved a cash dividend distribution ratio of 80.18% for the year, amounting to a total cash dividend of approximately 107 million yuan[15]. - The company has a high cash dividend ratio of 81.31%, distributing 0.87 yuan per 10 shares to shareholders[175]. - The total pre-tax remuneration for the board members and senior management during the reporting period amounted to 804.12 million yuan[180].

证券代码：600488 证券简称：津药药业 编号：2025-017 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、2024 年度利润分配预案内容 （一）利润分配预案的具体内容 经中审华会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日，公司期末可供分配利润为 918,900,698.29 元。公司董事会拟定的本次 利润分配预案为：拟以公司 2024 年度利润分配股权登记日的总股本为基 数，向全体股东每 10 股派发现金红利 0.98 元（含税）。截至 2024 年 12 月 31 日，公司总股本 1,091,886,680 股，以此计算合计分配现金红利 107,004,894.64 元（含税），本年度公司现金分红比例为 80.18%，剩余 811,895,803.65 元结转以后年度分配。 如在本公告披露之日起至实施权益分派股权登记日期间，公司总股本 发生变动的，公司拟维持每股分配比例不变，相应调整分配总额。如后续 总股本发生变化，将另行公告具 ...

Financial Performance - The company reported a net profit of 133 million yuan for the year 2024, representing a year-on-year increase of 13.68% compared to 117 million yuan in 2023 [1] - Basic earnings per share increased to 0.122 yuan from 0.107 yuan, marking a growth of 14.02% [1] - Total revenue decreased to 3.215 billion yuan from 3.783 billion yuan, reflecting a decline of 15.01% [1] - The return on equity rose to 4.45% from 3.95%, indicating a growth of 12.66% [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 65,134,180 shares, accounting for 59.66% of the circulating shares, with a decrease of 274,150 shares compared to the previous period [2] - Tianjin Pharmaceutical Group Co., Ltd. remains the largest shareholder with 55,453,010 shares, representing 50.79% of the total share capital [3] - Morgan Stanley & Co. International PLC entered the top ten shareholders with 206,090 shares [3] Dividend Distribution - The company announced a dividend distribution of 0.98 yuan per share (including tax) [4]

Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received the drug registration certificate for Naloxone Hydrochloride Injection from the National Medical Products Administration [1] - The drug is an opioid receptor antagonist, and the company has invested approximately 4.2 million yuan in the research and development of this product [1][2] - The domestic sales of Naloxone Hydrochloride Injection were 413 million yuan in 2022 and are projected to be 535 million yuan in 2023, indicating a growth in market demand [2] Group 2 - The approval of the drug registration certificate enhances the company's formulation product portfolio and is expected to positively impact the company's performance in the domestic formulation market [3] - However, the sales timeline, scale, and future expansion of the drug in the domestic market remain uncertain due to competitive market conditions [3]

证券代码：600488 证券简称：津药药业 编号：2025-014 津药药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司湖北津药药业股份有 限公司（以下简称"湖北津药"）收到国家药品监督管理局核准签发的关于盐酸纳洛 酮注射液（以下简称"该药品"或"本品"）的《药品注册证书》。现将相关情况公 告如下： | 药品名称 | 盐酸纳洛酮注射液 | | --- | --- | | 剂型 | 注射剂 | | 申请事项 | 药品注册（境内生产） | | 规格 | 1ml：1mg 2ml：2mg | | 注册分类 | 化学药品 3 类 | | 药品注册标准编号 | YBH03972025 | | 受理号 | CYHS2302206 CYHS2302207 | | 证书编号 | 2025S00714 2025S00715 | | 药品批准文号 | 国药准字 H20253614 国药准字 H20253615 | | 上市许可持有人 | 名 ...

证券代码：600488 证券简称：津药药业 编号：2025-013 津药药业股份有限公司 通过美国 FDA 关于 cGMP 现场检查的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 津药药业股份有限公司（以下简称"公司"）于2024年12月9日 至2024年12月13日期间接受了美国食品药品监督管理局（以下简称 "FDA"）的cGMP （现行药品生产质量管理规范）现场检查。近日， 公司收到FDA签发的现场检查报告（EIR，Establishment Inspection Report），该报告表明公司生产场地已通过本次cGMP现场检查，现将 相关情况公告如下： 一、FDA 现场检查的相关信息 公司名称：津药药业股份有限公司 注册地址：天津开发区西区新业九街19号 检查事由：美国食品药品监督管理局 FDA 的cGMP检查 检查范围：泼尼松、螺内酯以及其他皮质激素原料药 FDA FEI：3008256667 检查结果：以VAI（自愿行动指示）的结果顺利通过 二、对公司的影响及风险提示 本次FDA现场检查，以VAI的结果顺利通过，表明公司在药品质量 ...

证券代码：600488 证券简称：津药药业 编号：2025-012 津药药业股份有限公司 关于获得食品生产许可证的公告 7.食品类别：食品添加剂 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于近日收到天津市滨海新区市 场监督管理局颁发的《食品生产许可证》，类别为食品添加剂。现将相关情况公 告如下： 一、食品生产许可证的相关情况 1.生产者名称：津药药业股份有限公司 2.许可证编号：SC20112010404861 3.法定代表人（负责人）：李书箱 4.统一社会信用代码：9112000071824811X4 5.住所：天津开发区西区新业九街19号 6.生产地址：天津开发区西区新业九街19号 2 / 2 8.发证机关：天津市滨海新区市场监督管理局 9.品种明细：L-盐酸赖氨酸(提纯)、L-丙氨酸(提纯)、L-精氨酸(提纯)、L- 苏氨酸(提纯)、L-谷氨酸(提纯)、L-缬氨酸(提纯)、L-亮氨酸(提纯)、L-异亮氨 酸(提纯)、L-苯丙氨酸(提纯)、L-色氨酸(提纯)、甘氨酸(提纯 ...